secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058194
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan reports Q1 2024 results: net loss $30.1M, first solid tumor patient dosed, heme patients relapse-free
--------------------------------------------------------------------------------

- Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.
- First patient dosed in Phase 1 solid tumor trial with TSC-203-A0201 targeting PRAME; initial data expected H2 2024.
- All eight heme treatment-arm patients relapse-free with median follow-up >10 months; two control patients relapsed.
- Closed upsized $167.8M public offering in April; cash and marketable securities $162.8M at March 31, extending runway to Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/0000950170-24-058194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/tcrx-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer